Healthy Donors Exhibit a CD4 T Cell Repertoire Specific to the Immunogenic Human Hormone H2-Relaxin before Injection.


Journal

Journal of immunology (Baltimore, Md. : 1950)
ISSN: 1550-6606
Titre abrégé: J Immunol
Pays: United States
ID NLM: 2985117R

Informations de publication

Date de publication:
15 06 2019
Historique:
received: 18 06 2018
accepted: 11 04 2019
pubmed: 19 5 2019
medline: 7 3 2020
entrez: 19 5 2019
Statut: ppublish

Résumé

H2-relaxin (RLN2) is a two-chain peptide hormone structurally related to insulin with a therapeutic potential in multiple indications. However, multiple injections of human RLN2 induced anti-RLN2 Abs in patients, hampering its clinical development. As T cell activation is required to produce Abs, we wondered whether T cells specific for RLN2 might be already present in the human blood before any injection. We therefore quantified the RLN2-specific T cell repertoire using PBMCs collected from healthy donors. CD4 T cells were stimulated in multiple replicates by weekly rounds of stimulation by dendritic cells loaded with RLN2, and their specificity was assessed by IFN-γ ELISPOT. The number of specific T cell lines was used to estimate the frequency of circulating T cells. In vitro T cell response was demonstrated in 18 of the 23 healthy donors, leading to the generation of 70 independent RLN2-specific T cell lines. The mean frequency of RLN2-specific CD4 T cells was similar to that of T cells specific for known immunogenic therapeutic proteins. Using overlapping peptides, we identified multiple T cell epitopes hosted in the N-terminal parts of the α- and β-chains and common to multiple donors, in agreement with their capacity to bind to multiple HLA-DR molecules. Our results provide important clues to the immunogenicity of RLN2 and highlight the weak central immune tolerance induced against this self-hormone.

Identifiants

pubmed: 31101669
pii: jimmunol.1800856
doi: 10.4049/jimmunol.1800856
doi:

Substances chimiques

Autoantigens 0
Epitopes, T-Lymphocyte 0
HLA-DR Antigens 0
RLN2 protein, human 0
Interferon-gamma 82115-62-6
Relaxin 9002-69-1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3507-3513

Informations de copyright

Copyright © 2019 by The American Association of Immunologists, Inc.

Auteurs

Aurélien Azam (A)

Biologics Research, Sanofi Research and Development, 94400 Vitry sur Seine, France.
Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA)-Saclay, Université Paris-Saclay, Service d'Ingénierie Moléculaire des Protéines, 91191 Gif-sur-Yvette, France.

Yann Gallais (Y)

Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA)-Saclay, Université Paris-Saclay, Service d'Ingénierie Moléculaire des Protéines, 91191 Gif-sur-Yvette, France.

Sergio Mallart (S)

Integrated Drug Discovery, Sanofi Research and Development, 91380 Chilly Mazarin, France; and.

Stephane Illiano (S)

Cardiovascular Diseases and Metabolism, Sanofi Research and Development, 91380 Chilly Mazarin, France.

Olivier Duclos (O)

Integrated Drug Discovery, Sanofi Research and Development, 91380 Chilly Mazarin, France; and.

Catherine Prades (C)

Biologics Research, Sanofi Research and Development, 94400 Vitry sur Seine, France.

Bernard Maillère (B)

Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA)-Saclay, Université Paris-Saclay, Service d'Ingénierie Moléculaire des Protéines, 91191 Gif-sur-Yvette, France; bernard.maillere@cea.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH